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Abstract 23 
Candida auris is an emerging worldwide concern. While many studies focus on the 24 
pathomechanism of this peculiar fungus, comparative data about the virulence of different 25 
C. auris lineages in mammalian hosts is lacking. Different isolates of the four prevalent C. 26 
auris clades (South Asian n=5, East Asian n=4, South African n=5, and South American 27 
n=5) were compared to assess their virulence in a neutropenic murine bloodstream 28 
infection model with C. albicans as reference. C. auris, regardless of clade, proved to be 29 
less virulent than C. albicans. Highest overall mortality at day 21 was observed for the 30 
South American clade (96%, range 90%-100%), followed by the South Asian clade (80%, 31 
range 50%-100%), while East Asian and South African clades produced significantly 32 
lower cumulative lethality (44% and 45%, ranges 30-70% and 0-90%, respectively). 33 
Survival differed significantly among isolates of the same clade in case of all lineages. 34 
Fungal burden results showed close correlation with lethality. The highest fungal burden at 35 
day six was found with the South American clade. Histopathological examination revealed 36 
large aggregates of blastoconidia and budding yeast cells in the hearts, kidneys and livers 37 
but not in the spleens. The myocardium of apparently healthy sacrificed mice as well as of 38 
mice found moribund showed contraction band necrosis in case of all lineages. Regardless 39 
of clade, the heart and kidneys were the most heavily affected organs. Isolates of the same 40 
clade showed differences in virulence in mice, but a markedly higher virulence of the 41 
South American clade was clearly demonstrated. 42 
  43 
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Introduction 44 
Candida auris was first identified in 2009 at a geriatric hospital in Japan and then in a 45 
nosocomial fungemia in Korea in 2011 [1,2]. Retrospective identification by DNA 46 
sequencing revealed the earliest known strain of C. auris was a bloodstream isolate from 47 
1996 in a paediatric surgery patient in Korea, and the next earliest was found in 2008 in 48 
Pakistan [3]. In the last decade C. auris became an emerging organism with a public health 49 
significance causing asymptomatic colonization (skin, urine, indwelling devices) as well as 50 
sporadic hospital-acquired invasive infections (i.e. candidemia, intra-abdominal infections) 51 
worldwide [4]. Clinical studies showed that while C. auris affects both children and adults, 52 
it has been identified predominantly in critically ill patients in intensive care units [4-6]. 53 
Moreover, this pathogen is commonly multidrug resistant, posing a therapeutic challenge, 54 
however, susceptibility profiles may vary widely across isolates [4,7]. 55 
Five phylogenetically distinct clades (South Asian, East Asian, South African, South 56 
American and Iranian) of C. auris were identified based on whole genome sequence data 57 
of global clinical isolates [3,8]. Each clade differs from the other clades by >200,000 58 
single-nucleotide polymorphisms, but isolates from the same clade are highly clonal, 59 
suggesting emergence of C. auris on all continents almost simultaneously. 60 
The growing body of data suggest that significant differences exist between the five clades 61 
regarding their phenotypic characteristics and virulence [4,9,10]. In previous studies we 62 
have demonstrated that isolates belonging to South African and East Asian clades grew 63 
better in the presence of actidione, but do not produce even rudimentary pseudohyphae in 64 
Dalmau cultures as compared to South Asian clade [9]. The vast majority (84%) of South 65 
African isolates produce large aggregates in aqueous suspension on microscope slides and 66 
these isolates proved to be significantly less virulent in Galleria mellonella than the non-67 
aggregating isolates of the South Asian lineage [10]. Moreover, isolates belonging to the 68 
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South Asian, South African and South American clades but not the East Asian clade 69 
frequently cause outbreaks of invasive infections [4,11]. A single isolate representing a 70 
novel Iranian clade has been recently reported, but data on its pathogenicity and virulence 71 
is lacking [8].  72 
Data about in vivo virulence of different C. auris clades in mammalian hosts is scant, the 73 
available studies focus mainly on the South Asian clade [12-17], moreover, the South 74 
African clade has never been examined. Fakhim et al. infected ICR outbred 75 
immunocompetent mice with inocula of 10
5
-, 10
6
 and 10
7
 CFU/mouse using two C. auris 76 
(both from the South Asian clade) and one C. albicans strains. They did not find 77 
statistically significant differences regarding lethality (60-80%) or fungal tissue burdens 78 
between C. auris and C. albicans [12]. In contrast, a single C. auris isolate from the South 79 
Asian clade proved to be significantly less virulent (0% lethality) than C. albicans (100% 80 
lethality) despite the 10-fold lower intravenous inocula of C. albicans in an 81 
immunocompetent BALB/c mouse model [13]. In another study using a temporarily 82 
neutropenic BALB/c murine model, 7x10
7
 CFU/mouse inoculated intravenously produced 83 
significantly shorter survival of mice with C. albicans than with the one C. auris isolate 84 
from the South Asian clade tested [14]. In a further study with two South Asian isolates 85 
even 10
8
 CFU/mouse did not cause death in immunocompetent BALB/c mice, but using 86 
immunosuppression with neutrophil-depleting antibodies (RB6-8C5 and 1A8) led to 100% 87 
lethality with the same dose [15]. Similar lethality (100%) was obtained by Singh et al. 88 
with a single South Asian isolate, using 5x10
7
 CFU/mouse inoculated intravenously in a 89 
deeply neutropenic CD-1 murine model [16]. 90 
Xin et al., intravenously infected four different mouse strains with single C. auris isolates 91 
from the East Asian and South American lineages. They did not find lethality in BALB/c, 92 
neutrophil elastase-deficient and C57BL/6 non-neutropenic mice and only a few deaths in 93 
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neutropenic models even using an infectious dose as high as 2x10
8
 CFU/mouse. In 94 
contrast, the same dose produced 100% mortality within 2 days in A/J mice with C5 95 
complement factor deficiency [17].  96 
In this study we compared the behaviour of 17 clinical isolates derived from sterile and 97 
non-sterile body sites belonging to four C. auris lineages (South Asian, East Asian, South 98 
African, and South American) using a neutropenic murine bloodstream infection model. 99 
We also tested two additional C. auris isolates of environmental origin from the South 100 
American clade. As previous data from the G. mellonella model have suggested that at 101 
least some C. auris isolates showed virulence similar to C. albicans, we included two C. 102 
albicans bloodstream isolates in the same model for comparison [10].  103 
  104 
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Materials and methods 105 
Isolates 106 
Isolates of the four prevalent C. auris clades (South Asian n=5, East Asian n=4, South 107 
African n=5, South American n=5) tested, their origin and the origin of the C. albicans 108 
isolates are listed in Table 1. C. auris isolates were identified by a combination of 109 
ribosomal DNA gene sequencing targeting the 28S rRNA and/or ITS1 regions, which was 110 
also used for clade delineation [9,10]. C. albicans isolates were derived from a previous 111 
study [18]. Strains were stored at –70 
o
C. Two days before the in vivo experiments, isolates 112 
were subcultured using Sabouraud agar and screened on CHROMagar Candida (Becton 113 
Dickinson) to ensure purity of Candida isolates.  114 
 115 
Preparation of inocula 116 
Yeast inocula were initially prepared in sterile saline, but in case of the South African 117 
isolates large, visible and highly stable aggregates were observed in the tubes or in the 118 
syringes at 10
6
 and 10
7 
CFU/mL; homogeneous suspensions were never obtained in saline. 119 
Aggregate formation was never observed with the other three C. auris clades nor with C. 120 
albicans isolates. Thus, to avoid aggregate formation, inocula were prepared in phosphate-121 
buffered saline (PBS) and washed three times. 122 
 123 
Mice and immunosuppression 124 
In our preliminary experiments with immunocompetent BALB/c mice using inoculum 125 
densities of 10
6
 and 10
7 
CFU C. auris per mouse prepared in PBS all mice survived. With 126 
the isolates of the South African clade aggregating in saline (but not with the three 127 
aggregating isolates from the East Asian lineage, Table 1), infectious doses >10
7 
CFU/mice 128 
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produced early mortality (within one day) in 10-40% of mice, most probably due to 129 
embolization by fungal aggregates, which were either too small to be visible to the naked 130 
eye or produced in vivo. As early mortality were never observed at lower cell densities, we 131 
abandoned the immunocompetent model and used an immunocompromised murine model 132 
with the lower 10
7
 CFU/mouse inoculum for all four lineages to allow robust comparisons. 133 
BALB/c male mice (23-25 g) were given cyclophosphamide 4 days before infection (150 134 
mg/kg), 1 day before infection (100 mg/kg), 2 and 5 days post-infection (100 mg/kg) in the 135 
fungal tissue burden experiments; in the lethality experiments, immunosuppression was 136 
continued by administration of 100 mg/kg cyclophosphamide every third day until the end 137 
of the experiment at the 21
st
 day [18]. The Guidelines for the Care and Use of Laboratory 138 
Animals were strictly followed during maintenance of the animals; experiments were 139 
approved by the Animal Care Committee of the University of Debrecen (permission no. 140 
12/2014).  141 
 142 
Lethality experiments 143 
Mice (groups of ten mice/isolate) were infected intravenously through the lateral tail vein 144 
(day 0). The infectious dose for C. auris and C. albicans were 10
7 
and 10
5 
CFU/mouse, 145 
respectively, in volumes of 0.2 mL. Inoculum densities were confirmed by plating serial 146 
dilutions on Sabouraud agar plates.  147 
Mice were monitored twice daily for lethality for 21 days. Animals that became immobile 148 
or showed signs of severe illness were terminated and recorded as dying on the following 149 
day. Dead animals (1-2 from each clade) were dissected for histopathology. Survival rates 150 
were compared within the same clade using the Kaplan-Meier logrank test; then data of 151 
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isolates of the same clade were aggregated and survival was also analysed between 152 
different fungal clades [18]. Statistical tests were performed in Graph Pad 6.0.3.  153 
 154 
Fungal kidney tissue burden experiments 155 
The infectious doses for C. auris and C. albicans were 10
7 
and 5x10
4 
CFU/mouse, 156 
respectively. Two C. auris isolates of each clade and one C. albicans isolate were chosen 157 
based on the lethality experiments (Table 1). One group included eleven mice. On day two 158 
and six, five mice were sacrificed; both kidneys, the heart, the liver and the spleen were 159 
removed from each animal, weighed and homogenized aseptically in 1 ml of saline; the 160 
resulting tissue suspension was serially diluted. Fungal tissue burden was determined by 161 
quantitative culturing. The lower limit of detection was 100 CFU/g of tissue [18].  162 
Mean fungal tissue burdens produced by different isolates/clades in the same organs on 163 
day 2 or 6 were compared using the Kruskal-Wallis test with Dunn’s post-test. T test (with 164 
Welch's correction, where appropriate) was used to compare the mean fungal tissue 165 
burdens at day 2 with day 6 for the same organ with each isolate [18]. 166 
 167 
Histopathology 168 
Two mice from two different groups representing each clade (eight isolates altogether) 169 
derived from the fungal tissue burden experiments were used for histopathological 170 
examination on day 6. Seven mice freshly found dead in the lethality experiment (infected 171 
with C. auris type strain (NCPF 13029=CBS 10913), isolates CBS 12372, 2 (NCPF 8977), 172 
27 (NCPF 89891), I-24, I-172, and CDC B-13108) were dissected and analysed similarly. 173 
Moreover, on day 1 a single mouse infected with isolates 196, CBS 12373, 204 and I-24 174 
(representing each clade) were used to determine the early heart involvement. Organs 175 
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(heart, both kidneys, liver and spleen) were fixed in formalin and embedded in paraffin. 176 
Tissue sections (4 µm) were stained with haematoxylin-eosin and Periodic Acid Schiff 177 
(PAS). Hearts were stained with Mallory's phosphotungstic acid haematoxylin (PTAH) as 178 
well.  179 
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Results 180 
Lethality 181 
Candida auris. Mice infected with different C. auris isolates, with the exception of the 182 
isolates from Israel (South American clade), did not show clinical signs of systemic 183 
infection. Death occurred unexpectedly; one day before their death mice appeared 184 
clinically normal. Torticollis or other signs of the central nervous system involvement were 185 
never observed. Highest overall mortality at day 21 was observed for the South American 186 
clade (96%, range 90%-100%), followed by South Asian isolates (80%, range 50%-100%), 187 
while infection with South African and East Asian isolates resulted in markedly lower 188 
cumulative lethality (45% and 44%, ranges 0-90% and 30-70%, respectively) (Figs 1 and 189 
S1). Survival differed significantly within clades (P=0.0005, P=0.0010, P<0.0001 and 190 
P=0.0255 for South American, South Asian, South African and East Asian clades, 191 
respectively). In cases of the South American and South Asian clades mortality was first 192 
observed at days 3 and 4, respectively. All mice inoculated with isolates from Israel (South 193 
American clade) died by day 11. In contrast, late onset of mortality (later than day 8) was 194 
typical for South African and East Asian clades (Fig. 1). Notably, the two bloodstream 195 
isolates from the East Asian clade caused higher mortality (50-70% vs. 30%) than isolates 196 
from external ear samples. However, isolate 206 (a bloodstream isolate from the South 197 
African clade) did not kill any mice during the 21-day experiment.  198 
Candida albicans. The two C. albicans isolates using a 100-fold lower inoculum than C. 199 
auris produced 90-100% mortality rates with typical signs (lethargy, loss of appetite, 200 
hunched back, and ruffled fur) of systemic infection (P>0.05) (Fig. 2).  201 
 202 
  203 
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Fungal organ tissue burden  204 
Candida auris. Regardless of clade, the heart and kidneys were the most heavily affected 205 
organs. Fungal burden results showed close correlation with lethality, i.e. infection with 206 
isolates causing high mortality in the lethality experiments within each clade produced 207 
higher fungal tissue burdens (Fig. 1). Six-day heart and kidney burdens with the isolates 208 
causing high lethality (>=90%) were at least one order of magnitude higher than burdens 209 
caused by isolates associated with intermediate or low lethality (30-60%). This was 210 
apparent even at day 2 in case of heart burdens. Kidney and heart burdens tended to 211 
increase from day 2 to day 6 in case of highly lethal isolates, but not for isolates causing 212 
intermediate-low lethality. In case of the South Asian, East Asian and South African 213 
clades, the lower-lethality isolates produced lower fungal burdens, highly lethal isolates 214 
produced higher burdens, while in case of the South American clade both tested isolates 215 
produced high lethality and high burdens (Fig. 1).  216 
Spleen and liver burdens were more variable. Mean fungal spleen burdens at day 2 did not 217 
differ significantly between isolates, but at day 6 CFU number of the isolate 16565 (South 218 
American clade) was significantly higher than those for isolates 15 (NCPF 8984) and 164 219 
(East Asian and South Asian clades, respectively) (P<0.001) (Fig. 1). Mean fungal liver 220 
burdens were the lowest on both tested days compared to other examined organs; the 221 
highest (3.6x10
6
 CFU/g) and lowest (6.5x10
3
 CFU/g) mean fungal burdens were noticed in 222 
cases of high-lethality isolates 196 and intermediate-lethality 164, respectively, (both 223 
belonging to South Asian lineage) at day 2.  224 
Candida albicans. Fungal tissues burden increases with isolate 3666 were statistically 225 
significant in cases of heart, kidneys and spleen (P=0.016, P=0.008 and P=0.008, 226 
respectively) from day 2 to day 6. Mean fungal liver burdens at days 2 and 6 were lower 227 
than 10
4
 CFU/g (Fig. 2).  228 
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Mean fungal heart and kidney burdens were comparable to those with high-lethality C. 229 
auris isolates at day 6, but were higher than in case of C. auris isolates causing 230 
intermediate or low lethality. However, mean liver fungal burden was significantly lower 231 
than isolates 16565 and 196 of C. auris (both being high-lethality isolates) (Figs 1 and 2). 232 
 233 
Histopathology 234 
Candida auris. Only single yeast cells and numerous budding yeast cells were produced in 235 
the organs, pseudohyphae were never observed. However, all isolates produced numerous, 236 
large aggregates in all examined organs with the exception of the spleen, both in mice 237 
dissected during the fungal burden experiments and in mice found dead in the lethality 238 
experiments (Fig. 3).  239 
All examined hearts (regardless of clade) exhibited multiple foci of abundant yeast cells 240 
between myofibers with coagulative necrosis of myocytes (Fig. 3). Myofibers were 241 
frequently distorted by the fungal lesions. Mallory's PTAH staining revealed that 242 
myocardial fibers lost their cross-striations, confirming the contraction band necrosis or 243 
myofibrillar degeneration in all mice freshly found dead in the lethality experiments (Fig. 244 
4A, B) [19]. Contraction band necrosis was found in infected but apparently healthy mice 245 
dissected on day 6 as well. Early heart involvement on day 1 was confirmed by detecting 246 
clumps of blastoconidia and budding yeast cells filling the arterioles of the myocardium 247 
(Fig 4C). Foci appeared in the sub-endocardial myocardium and the pericardium only in 248 
late stages of the infection. 249 
In the kidneys, there was evidence of multifocal infiltration with C. auris within the 250 
parenchyma, with focal destruction of tubuli, but glomeruli were not affected. Necrotising 251 
areas were frequently seen (Fig. 3). In the livers C. auris produced large, multifocal 252 
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lesions; the dilated liver sinusoids were filled with abundant yeast cells, fungi spread 253 
radially in the liver parenchyma with central necrosis of lobuli. Vacuolar degeneration of 254 
hepatocytes was commonly seen (Fig. 3). In the spleens, in contrast, only small clumps of 255 
fungal cells were seen (Figs 3 and 4D).  256 
Candida albicans. In the heart, kidneys and spleen abundant single and budding yeast 257 
cells, pseudohyphae and hyphae were seen (Fig. 3). In the liver only small number of 258 
blastoconidia and budding yeast cells and pseudohyphae were noticed (Fig. 3). In the heart 259 
large necrotic areas were seen involving the endo- and myocardium but without 260 
contraction band necrosis (Fig. 3).  261 
 262 
  263 
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Discussion 264 
The most common clinical presentation of C. auris infection is candidemia in intensive 265 
care units among critically ill patients. Major risk factors are diabetes mellitus, surgical 266 
cardiovascular and gastrointestinal diseases, haematological malignancies and 267 
corticosteroid therapy [3-6,20-23]. Interestingly, neutropenia is not considered as an 268 
important risk factor for invasive C. auris infection. This clinical experience may be 269 
related with the in vitro finding that C. auris triggers neutrophil engulfment and production 270 
of neutrophil extracellular traps less effectively compared to C. albicans [24]. However, 271 
Chowdhary et al. have reported 6 of 12 patients with C. auris candidemia with neutropenia 272 
[25]. Candidemia is frequently persistent in spite of apparently adequate targeted 273 
antifungal therapy; septic metastatic complications (i.e. spondylodiscitis, endo- and 274 
pericarditis) are also often encountered [2,4, 22,23]. Kidneys are often involved in the 275 
pathogenesis as well, both in cases with or without candidemia [4-7,20-23,25,26]. The 276 
crude in-hospital mortality rate for C. auris candidemia may be as high as 68-80% (3,22). 277 
Attributable mortality due to C. auris is hard to determine due to the severe underlying 278 
conditions of the patients; limited available estimates fall between 22.2 to 66.6% 279 
[2,6,23,26,27].  280 
Data on clade-specific mortality are scant. In the first reported cases of C. auris 281 
candidemia two of three patients infected with the East Asian clade died in Korea and 282 
showed persistent candidemia in spite of fluconazole and amphotericin B treatment [2]. 283 
Lockhart et al. reported 47-72%, 60% and 33% mortality rate with South Asian, South 284 
American and South African clades, respectively [3].  285 
Our lethality results in a deeply neutropenic murine model were consistent with other 286 
groups showing that C. auris, regardless of clade, is less virulent than C. albicans 287 
[13,14,17]. In this study, the ranking in the virulence of the four C. auris clades was South 288 
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American> South Asian>South African=East Asian (Figs 1, 2 and S1). Similar high 289 
virulence was reported by Xin et al. in A/J (100% lethality) but not in BALB/c neutropenic 290 
mice (40% lethality) using a single South American isolate [17]. Our lethality results with 291 
the South Asian clade (50-100% lethality) correlate well to those previously reported for 292 
neutropenic BALB/c or CD-1 mice (40-100% lethality) with the same or higher (from 10
7
 293 
to 10
8
 CFU/mouse) infectious doses [15,16]. The lack of similar studies with the South 294 
African clade precludes comparison to our results. However, we confirmed the previous 295 
observation in a G. mellonella model that aggregating South-African C. auris isolates are 296 
less virulent than non-aggregating South-African isolates [10]. Moreover, we found 297 
significant differences in virulence among isolates of the same clade in case of virtually all 298 
clades. These results are concordant with the previous in vitro findings that C. auris 299 
isolates may produce several virulence factors in a strain-dependent manner but to a lower 300 
extent than C. albicans (4,28). Notably, the C. auris isolates from the South American 301 
clade originating from bloodstream infection and the hospital environment produced very 302 
similar mortality rates at day 21 (100% and 90%, respectively). This highlights that 303 
virulent C. auris persists for long periods in the hospital environment and these isolates are 304 
potential sources of colonization and infection for high risk patients [3-5,23,27]. 305 
High fungal tissue burdens supported our histopathological findings regardless of clade; at 306 
day six multifocal, large aggregates of single and budding yeast cells were always found in 307 
the hearts, kidneys and livers but not in the spleens (Fig. 3). Interestingly, these lesions 308 
were detected both with aggregating and non-aggregating isolates, suggesting that both 309 
phenotypes behave similarly in vivo. These large yeast cell aggregates in tissues may shield 310 
the fungus from the effective immune response and promote fungal persistence and 311 
replication [4,10,11]. Moreover, it cannot be ruled out that homogenization of these large 312 
tissue aggregates was not perfectly successful and despite homogenization, some cells 313 
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might have remained aggregated, thus the CFU numbers may have been underestimated. 314 
This may explain why some isolates (i.e. isolate 164 from the South Asian clade) showed 315 
unexpectedly less CFU on day 6 than day 2.  316 
Large, multifocal lesions in the myocardium without involvement of the endocardium 317 
suggest hematogenous seeding; on day 1 abundant single and budding yeast cells were 318 
seen in the coronary arteriolae in mice infected with all C. auris lineages (Fig. 4C). Our 319 
results are in accordance with others who observed high fungal burdens (≥x10
5
 CFU/g) in 320 
the myocardium with BALB/c, A/J, neutrophil elastase-deficient and C57BL/6 neutropenic 321 
and non-neutropenic mice infected with C. auris isolates from the South American and 322 
South Asian clades [15,17]. In contrast, with the more virulent C. albicans endocardial 323 
involvement was found and myocardial involvement was primarily subendocardial, 324 
suggesting a penetration of the heart muscle by yeasts starting from the endocardium. 325 
In spite of the high fungal burden in the heart even at day 2 (≥5.2x10
5
 CFU/g), increased 326 
early mortality was not observed with the less virulent isolates from the South African, 327 
East Asian and South Asian lineages. However, the heavy myocardial fungal burden is 328 
associated with irreversible damage of the myocardial cells as detected by the contraction 329 
band necrosis (Fig 4B) found in apparently healthy dissected mice as well as in mice 330 
freshly found dead. Translating our results to clinical situations, delay in the diagnosis and 331 
treatment of disseminated C. auris candidiasis may increase the risk for fungus-induced 332 
myocardial failure and sudden death.  333 
High fungal kidney and/or heart burdens are frequently associated with heavy fungal 334 
burden in the brain and lungs as reported both in immunocompetent and neutropenic mice. 335 
Singh et al., noticed simultaneously heavy fungal kidney (2x10
8
 CFU/g) and brain (2x10
6
 336 
CFU/g) burdens. Interestingly, C. auris cells found in the brain were localized mainly in 337 
the capillaries rather than in the cerebral tissue itself [16]. Candida pneumonia is a rare 338 
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manifestation of invasive Candida infections in humans, but in immunocompetent ICR and 339 
BALB/c mice higher infectious doses (≥10
7
 CFU/g) produced 10
3
->10
5
 CFU/g lungs tissue 340 
burdens [12,13]. Although in this study we did not examine the fungal burdens in the brain 341 
and lungs, based on the high fungal burdens in the hearts and kidneys, central nervous 342 
system and lung invasion is also feasible. However, we did not observe signs of meningeal 343 
involvement [15].  344 
To our best knowledge this is the first study to compare the in vivo virulence of the four C. 345 
auris lineages distributed worldwide in a mammalian host. We observed high fungal 346 
burdens in organs, especially in the myocardium, confirming that the heart is a major target 347 
in cases of disseminated C. auris infection. However, failure of other organs especially the 348 
kidney may contribute to mortality as well. Isolates of the same clade showed differences 349 
in murine virulence; a markedly higher virulence of the South American clade was clearly 350 
demonstrated both in case of bloodstream and hospital environmental isolates.  351 
  352 
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Figure legends 437 
Figure 1. 438 
Survival (left) and fungal tissue burden (right) of neutropenic BALB/c mice infected with 439 
the four Candida auris clades. In survival studies mice were infected with 19 isolates 440 
(South Asian n=5, East Asian n=4, South African n=5 and South American n=5) 441 
representing the four clades. In the graph representing the East Asian clade the ‘Type 442 
strain’ represents NCPF 13029 (CBS 10913) type strain isolated from external ear. Fungal 443 
kidney, spleen, liver and heart burdens were determined with isolates 196 and 164 from the 444 
South Asian, isolates 15 (NCPF 8984) and 12373 (CBS 12373) from the East Asian, 445 
isolates 206 (NCPF 13042) and 204 from the South African and isolates I-24 and 16565 446 
(CDC B-16565) from the South American clades at days 2 and 6. The bars represent the 447 
medians. 448 
 449 
Figure 2. 450 
Survival (left) of neutropenic BALB/c mice infected with Candida albicans isolates 3666 451 
and 2606. Fungal kidney, spleen, liver and heart burdens (right) was determined with 452 
isolate 3666 at days 2 and 6. The bars represent the medians. 453 
 454 
Figure 3. 455 
Histopathological examination of the heart, kidney, liver and spleen using Periodic Acid 456 
Schiff staining from neutropenic mice intravenously challenged with Candida albicans 457 
isolate 3666 (left panels) and C. auris isolate I-24 (right panels), respectively. 458 
Histopathological examination was performed six days post infection. In case of C. 459 
albicans in the heart, in the kidney and in the spleen blastoconidia and budding yeast cells, 460 
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pseudohyphae and hyphae were seen. In the liver hyphae were not detected. In the heart 461 
both endo- and myocardial involvement is noticeable, the subendocardial myocardium is 462 
affected most markedly. Signs of beginning blood vessel invasion in the myocardium is 463 
detectable (black arrow). In the kidney C. albicans was detected within the parenchyma, 464 
tubuli and glomeruli. In the spleen pseudohyphae and hyphae were seen in the red pulp. 465 
C. auris produced large aggregates in the heart, kidney and liver with numerous 466 
blastoconidia and budding yeast cells were detected. In the heart coagulative necrosis of 467 
myocytes was noticed. In the kidney C. auris cells were detected in the parenchyma, tubuli 468 
but not in the glomeruli. In the liver dilated liver sinusoids were filled with yeast cells with 469 
central necrosis of lobuli and vacuolar degeneration of hepatocytes. In the spleen yeast 470 
cells were seen at the border of the red and white pulp with focal destruction of the white 471 
pulp. Small fungal lesions were detectable under the capsule of the spleen and in the 472 
sinuses. Magnification × 100. 473 
 474 
Figure 4. 475 
Histological findings from neutropenic mice intravenously challenged with Candida auris.  476 
Normal (A) and damaged heart (B) with Mallory's PTAH staining. PTAH staining 477 
performed on the heart of a moribund dissected mouse on day 5 infected with isolate 196 478 
(B) revealed contraction band necrosis or myofibrillar degeneration (yellow arrows). 479 
Morphology of C. auris with Periodic Acid Schiff (PAS) staining in the heart’s arterioles 480 
on day 1 post infection (C), and in the spleen (D). PAS staining showed blastoconidia and 481 
budding yeast cells but never pseudohyphae and hyphae (C-D). Magnification, A-B × 400, 482 
C×1000, D×400, RBC; red blood cells. 483 
 484 
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Figure S1. Cumulative survival of neutropenic BALB/c mice infected with the four 485 
Candida auris clades. The infectious doses were 10
7
 CFU/mouse. 486 
